Glycated Albumin‐Guided Therapy: Biomarker Utility or Earlier Treatment Intensification?

Muhammet Fatih Şahin · 2026

Read Glycated Albumin‐Guided Therapy: Biomarker Utility or Earlier Treatment Intensification? by Muhammet Fatih Şahin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13620281.txt.

Description

Muhammet Fatih Şahin wrote a letter to the editor questioning a trial that used glycated albumin to guide early diabetes treatment. Glycated albumin reflects blood sugar over a shorter window than the standard HbA1c test, so the trial let doctors act sooner in newly diagnosed type 2 diabetes. The letter praises the multicenter randomized design, then presses on weak points in how the results were read.

The main target, reaching the standard HbA1c goal at twelve weeks, came out identical in both groups. A stricter goal looked better only under a secondary analysis that drops the protection of randomization, and many secondary comparisons went unadjusted. Şahin's sharpest point is mechanical: the guided group simply received far more combination therapy, so gains may credit earlier intensification rather than the biomarker itself. The letter asks for trials that separate the marker's value from the treatment push it triggers.

Catalog record

CREATORMuhammet Fatih Şahin
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE3 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13620281

Browse the full library · About the Tower of Babel